NASDAQ · Biotechnology

Chinook Therapeutics, Inc. (KDNY) Stock

$40.39 +0.22% NASDAQ: KDNY Healthcare

Chinook Therapeutics, Inc., a biotechnology enterprise in the clinical development phase, is dedicated to the identification, progression, and market introduction of precise medical treatments for kidney-related conditions. The company's primary therapeutic candidate, atrasentan, is an endothelin receptor antagonist currently in Phase III clinical trials.

Valuation

MetricValue
Price$40.39
Market Cap$2.71B
P/E Ratio-14.07
P/B Ratio5.88
P/S Ratio441.93
EPS (TTM)$-2.87
52-Week High$40.51
52-Week Low$18.34
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-41.23%
ROA-32.16%
ROCE-35.37%
Gross Margin71.90%
Operating Margin-3083.33%
Net Margin-3083.33%
Debt/Equity0.09
Current Ratio7.59

Annual Financials (USD)

Metric20182019202020212022
Revenue$15.0M$17.0M$1.0M$52.0M$6.0M
Operating Profit$-101.0M$-20.0M$-56.0M$-99.0M$-185.0M
Net Profit$-95.0M$-47.0M$-82.0M$-101.0M$-185.0M
EPS$0.00$-1.11$-6.20$-2.22$-2.87
Op Margin-671.8%-115.7%-6798.9%-191.8%-3020.3%

Balance Sheet (USD)

Metric20182019202020212022
Total Assets$358.0M$16.0M$429.0M$564.0M$574.0M
Total Liabilities$222.0M$57.0M$94.0M$110.0M$132.0M
Cash$126.0M$11.0M$188.0M$182.0M$115.0M
Borrowings$0$2.0M$42.0M$44.0M$39.0M

Latest News

Boeing Delivered 64 Jets in June. Here's What That Means for Its July 28 Earnings. Motley Fool · Jul 16, 2026 Netflix shares drop on growth worries AFP · Jul 16, 2026 Constellation Software Inc. Announces Conference Call to Discuss Second Quarter Results GlobeNewswire · Jul 16, 2026 Ola-Ola brand Authentic Pounded Yam (Iyan) IYANINSTANT recalled due to undeclared milk CNW Group · Jul 16, 2026 FormFactor and Kulicke and Soffa Shares Are Falling, What You Need To Know StockStory · Jul 16, 2026

Cash Flow (USD)

Metric20182019202020212022
Operating Cash Flow$-69.0M$-14.0M$-56.0M$-103.0M$-117.0M
Investing Cash Flow$37.0M$-2.0M$109.0M$-115.0M$-102.0M
Financing Cash Flow$-1.0M$1.0M$124.0M$210.0M$151.0M
Net Cash Flow$-31.0M$-115.0M$178.0M$-6.0M$-66.0M
Free Cash Flow$-71.0M$-14.0M$-57.0M$-105.0M$-119.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.21
EV / EBITDA-16.03
FCF Yield-4.40%
Quick Ratio7.59
Interest Coverage-25.78
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
BLUBELLUS Health Inc. $14.75 +0.03% -22.34 $1.87B 0.00%
CALTCalliditas Therapeutics AB (publ) $40.00 -0.10% -22.08 $2.15B 0.00%
DICEDICE Therapeutics, Inc. $47.55 +0.06% -22.97 $2.27B 0.00%
FUSNFusion Pharmaceuticals Inc. $21.55 +0.14% -14.86 $1.83B 0.00%
LBPHLongboard Pharmaceuticals, Inc. $59.98 — -25.10 $2.34B 0.00%

About Chinook Therapeutics, Inc.

Chinook Therapeutics, Inc., a biotechnology enterprise in the clinical development phase, is dedicated to the identification, progression, and market introduction of precise medical treatments for kidney-related conditions. The company's primary therapeutic candidate, atrasentan, is an endothelin receptor antagonist currently in Phase III clinical trials. This drug aims to treat IgA nephropathy and various other glomerular diseases characterized by proteinuria. Beyond its lead program, Chinook's investigational pipeline includes BION-1301, an anti-APRIL monoclonal antibody, which is presently being evaluated in a Phase I/II study for IgA nephropathy. Another promising candidate is CHK-336, an oral small molecule designed to inhibit LDHA, intended for patients with primary hyperoxaluria. The firm also maintains active research initiatives exploring solutions for other uncommon and severe chronic kidney ailments. Chinook Therapeutics, Inc. is based in Seattle, Washington.

Chinook Therapeutics, Inc. is headquartered in US.

Chinook Therapeutics, Inc. (KDNY) stock trades at $40.39 with a market capitalization of $2.71B. The stock is valued at a price-to-earnings (P/E) ratio of -14.07, price-to-book of 5.88, price-to-sales of 441.93. Over the past 52 weeks the stock has ranged between $18.34 and $40.51, and currently trades at its 52-week high.

On profitability, Chinook Therapeutics, Inc. generates a return on equity (ROE) of -41.23%, return on capital employed of -35.37%, an operating margin of -3083.33%, a net profit margin of -3083.33%.

Official website: www.chinooktx.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides